In the article on hexamer IgM for melanoma treatment, beginning on page 2745 of the May 1, 2007, issue of Clinical Cancer Research, the figures below should have appeared in color.
References
1
Azuma Y, Ishikawa Y, Kawai S, et al. Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma.
Clin Cancer Res
2007
;13
:2745
–50.American Association for Cancer Research
2007